Neumora Therapeutics Inc
NMRA
ISIN null / Valor 129329732
Neumora Therapeutics Inc
UMushroom community rating:
About company
Neumora Therapeutics Inc is a biotechnology firm dedicated to revolutionizing the treatment of brain diseases through innovative approaches in neuroscience. The company is at the forefront of developing medications aimed at addressing neuropsychiatric disorders and neurodegenerative diseases, which are known for their complexity and varied manifestations. Neumora's strategy involves targeting therapeutically relevant mechanisms within the central nervous system (CNS) with the goal of discovering treatments that are both novel and superior in their pharmacological effects. Additionally, the company employs a precision medicine framework to dissect the biological underpinnings of brain diseases, enabling the identification of specific patient groups who could benefit most from their therapies. This dual focus on groundbreaking pharmacology and targeted treatment approaches positions Neumora Therapeutics Inc as a key player in the quest to provide more effective solutions for conditions that have long challenged the medical community.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (12.10.2025):
Neumora Therapeutics Inc. reported its financial results for the fourth quarter and full year of 2024, demonstrating a strong cash position and continued investment in research and development. The company remains well-funded to support its operations into mid-2026 while advancing its pipeline of neuroscience programs.
Cash Position
As of December 31, 2024, Neumora Therapeutics Inc. held $307.6 million in cash, cash equivalents, and marketable securities, ensuring the company can sustain its operations through mid-2026.
Research & Development Expenses
R&D expenses increased to $45.9 million for the fourth quarter of 2024 from $38.9 million in the same period in 2023. For the full year, R&D costs rose to $200.9 million compared to $142.7 million in 2023, primarily due to the advancement of clinical trials for navacaprant.
General & Administrative Expenses
General and administrative expenses grew to $17.0 million in the fourth quarter of 2024, up from $11.2 million in Q4 2023. The full-year G&A expenses reached $62.5 million, an increase from $45.5 million in 2023, driven by higher personnel-related costs and the expansion of administrative functions.
Net Loss
Neumora reported a net loss of $58.8 million for the fourth quarter of 2024, a decrease from $108.7 million in Q4 2023. For the full year, the net loss was $243.8 million, compared to $235.9 million in the previous year.
Financial Guidance
The company expects its current cash reserves to fund its operating plan into mid-2026, providing stability as it continues to develop its pipeline of neuroscience programs.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
419 M
Market cap (USD)
706,898
Daily traded volume (Shares)
11.47 / 10.87
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Viktor Stockel
EQUITIES OF THE SAME SECTOR
